MapLight Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
MapLight Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, MapLight Therapeutics, Inc. Common Stock (MPLT) has a cash flow conversion efficiency ratio of -0.129x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.87 Million) by net assets ($348.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MapLight Therapeutics, Inc. Common Stock (2022–2025)
Cash flow conversion efficiency of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how MapLight Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MPLT stock price and chart for real-time trading data and today's change.
MapLight Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
MapLight Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MapLight Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MapLight Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see MapLight Therapeutics, Inc. Common Stock market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Qingdao Richmat Intelligence Technology Co. Ltd. A
SHE:301320
|
N/A |
|
Chengdu Shengbang Seals Co.Ltd.
SHE:301233
|
0.020x |
|
Arad Ltd
TA:ARD
|
0.064x |
|
Taewoong Co.Ltd
KQ:044490
|
-0.003x |
|
Malaysian Resources Corporation
KLSE:1651
|
-0.037x |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
0.068x |
|
Perpetual Equity Investment Company Ltd
AU:PIC
|
-0.011x |
|
Nanjing OLO Home Furnishing
SHG:603326
|
0.055x |
Annual Cash Flow Conversion Efficiency for MapLight Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025. Review MPLT financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $458.37 Million | $-138.14 Million | -0.301x | +55.95% |
| 2024-12-31 | $115.19 Million | $-78.81 Million | -0.684x | +6.22% |
| 2023-12-31 | $71.28 Million | $-52.01 Million | -0.730x | +42.71% |
| 2022-12-31 | $20.87 Million | $-26.58 Million | -1.273x | -- |
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more